异噁唑并[4,5-b]吡啶-3-胺 | 114080-93-2

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异恶唑并吡啶类
• 中文名称: 异噁唑并[4,5-b]吡啶-3-胺
• 中文别名: 异恶唑并[4,5-B]吡啶-3-胺；异噁唑并[4,5-B]吡啶-3-胺
• 英文名称: isoxazolo[4,5-b]pyridin-3-ylamine
• 英文别名: isoxazolo[4,5-b]pyridin-3-amine；[1,2]oxazolo[4,5-b]pyridin-3-amine
• CAS: 114080-93-2
• 化学式: C₆H₅N₃O
• 分子量: 135.125
• InChiKey: ZNDOHNLYFBVMMM-UHFFFAOYSA-N

物化性质

• 沸点：
  336.6±22.0 °C(Predicted)
• 密度：
  1.421±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-N-ethyl-4-methylbenzenesulfonamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-N-ethyl-4-methylbenzenesulfonamide
CAS number: 1017477-17-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H14N2O2S
Molecular weight: 214.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  异噁唑并[4,5-b]吡啶-3-胺 在 sodium tetrahydroborate 、 5%-palladium/activated carbon 、 水 、 氢气 、 sodium ethanolate 、 nickel dichloride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 生成 2-[2-(3-hydroxypyridin-2-yl)-6-oxo-1H-pyrimidin-5-yl]acetic acid
  参考文献：
  名称：

  Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

  摘要：

  The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were developed for the preparation of their analogs containing the new scaffolds. In addition, the structure-activity relationship (SAR) of the 2-[2-(3-hydroxy-pyridin-2yl)-thiazol-4-yl]-acetamide derivatives and their biological activities were reported. The complex structure of compound 18 with PHD2 was also obtained for the purpose of more efficient lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.003
• 作为产物：
  描述：

  2-氰基-3-氟吡啶 在 乙酰氧肟酸 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 16.0h， 以78%的产率得到异噁唑并[4,5-b]吡啶-3-胺
  参考文献：
  名称：

  制备异恶唑并吡啶-3-胺衍生物的高产率方法

  摘要：

  已经开发出一种高效且绿色的方法，用于以优异的产率快速制备高度官能化的异恶唑并吡啶-3-胺衍生物。该工艺具有广泛的基材范围，在操作上...

  DOI：

  10.1039/c6gc01125j

文献信息

• [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS À BASE D'URÉE À SUBSTITUTION HÉTÉROARYLE D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010068452A1

  公开（公告）日：2010-06-17

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化）。
• [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS D'URÉE SUBSTITUÉS PAR HÉTÉROARYLE D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010068453A1

  公开（公告）日：2010-06-17

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化）。
• SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS
  申请人：KÜHNERT Sven

  公开号：US20100234419A1

  公开（公告）日：2010-09-16

  The invention relates to substituted 3-aminoisoxazolopyridines, to processes for their preparation, to medicaments containing these compounds and to the use of these compounds in the preparation of medicaments.

  该发明涉及替代的3-氨基异噁唑吡啶类化合物，以及其制备方法、含有这些化合物的药物和这些化合物在药物制备中的应用。
• Design, synthesis and evaluation of new α-nucleophiles for the hydrolysis of organophosphorus nerve agents: application to the reactivation of phosphorylated acetylcholinesterase
  作者：Géraldine Saint-André、Maria Kliachyna、Sanjeevarao Kodepelly、Ludivine Louise-Leriche、Emilie Gillon、Pierre-Yves Renard、Florian Nachon、Rachid Baati、Alain Wagner

  DOI：10.1016/j.tet.2011.05.130

  日期：2011.8

  mechanism of their action was studied in details by kinetic analysis, HPLC and LC–MS methods. The most promising structures were then considered as potent in vitro reactivators of phosphylated acetylcholinesterase (AChE), which was confirmed by the preliminary results of AChE reactivation initially inhibited by VX.

  已经合成了一系列新的α-亲核试剂，包括肟和a胺肟，并评估了它们有效和选择性地裂解有机磷神经毒剂的PS键的能力。报道了α-亲核试剂的化学结构与其对PhX水解的反应性之间的关系。邻位引起的显着效果发现芳基-和吡啶基-肟的-羟基基团，a胺肟对它们的有机膦-硫代酶的反应性。对α-亲核试剂存在下PhX水解反应初始速率的评估，使得发现了与用作解毒剂的带正电荷的2-普萘定肟相比，具有增加的反应性的新的不带电荷分子。通过动力学分析，HPLC和LC-MS方法详细研究了它们的作用机理。然后，最有希望的结构被认为是磷酸化乙酰胆碱酯酶（AChE）的有效体外再活化剂，这一点已被最初被VX抑制的AChE再活化的初步结果所证实。
• Heterocyclic inhibitors of MEK and methods of use thereof
  申请人：Wallace Eli

  公开号：US20050153942A1

  公开（公告）日：2005-07-14

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 7 , R 8 and R 9 , W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐和前药，其中R1、R2、R7、R8和R9、W、X、Y和Z如规范中所定义。这些化合物是MEK抑制剂，可用于治疗哺乳动物的增殖过度疾病，如癌症和炎症，以及炎症病症。本发明还涉及使用这些化合物治疗哺乳动物的增殖过度疾病的方法和含有这些化合物的制药组合物。